Comparative Pharmacology
Head-to-head clinical analysis: TRICOR MICRONIZED versus TRILIPIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRICOR MICRONIZED versus TRILIPIX.
TRICOR (MICRONIZED) vs TRILIPIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tricor (micronized fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist that increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apolipoprotein C-III.
TRILIPIX (fenofibric acid) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase, and reduces production of apoprotein C-III.
Initial 48 mg (1 tablet) orally once daily with meals. May increase to 96 mg (2 tablets) once daily with meals. Maximum dose 96 mg/day.
135 mg orally once daily, not to exceed 135 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours (range 15-25 hours) in patients with normal renal function. Half-life is prolonged in renal impairment, requiring dose adjustment when eGFR < 30 mL/min/1.73 m².
Terminal elimination half-life of fenofibric acid is approximately 20 hours (range 10-35 hours), allowing once-daily dosing.
Primarily renal excretion of glucuronide conjugate, accounting for approximately 60-70% of elimination; fecal excretion accounts for about 25%. Minimal unchanged drug in urine.
Primarily renal excretion as glucuronide conjugate and unchanged drug; ~60% of dose excreted in urine as fenofibric acid and its glucuronide, ~25% in feces.
Category C
Category C
Fibrate Antilipemic
Fibrate Antilipemic